Price-hiked EpiPen profits 66% higher than Mylan CEO claimed
September 27, 2016Business Services, Manufacturing and Production, Sales and Marketing Heather Bresch, Mylan, epipen
In the latest development in the Mylan EpiPen scandal, it has been discovered that CEO Heather Bresch lied to US …
Sanofi secures $43 million government funding for zika vaccine development
September 27, 2016Manufacturing and Production, Research and Development BARDA, Sanofi, Zika
The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the …
Johnson & Johnson’s Stelara receives FDA approval
September 27, 2016Manufacturing and Production, Research and Development Janssen Biotech, Johnson & Johnson, Stelara
The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated …
Biogen closes in on bringing muscular atrophy preventing drug to market
September 26, 2016Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen
Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …
CPHI Worldwide: PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules
September 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CPhI
Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) …
Pfizer decides not to break up business
September 26, 2016Sales and Marketing Ian Read, Pfizer, United States, america
In the intervening four years, Pfizer has conducted “extensive evaluation” into the possibility, with the company reorganising into two distinct …
Australian pharmaceutical market to grow to be worth $25 billion by 2020
September 26, 2016Business Services, Sales and Marketing Australia, Australian Government
The Australian market, in 2016, is currently worth over $22.85 billion and is predicted to reach $25.2 billion by 2020, …
Sanofi and Regeneron’s atopic dermatitis drug secures FDA priority review
September 26, 2016Research and Development, Sales and Marketing
Regeneron and Sanofi have announced that the US Food and Drug Administration has granted priority review for the pair’s atopic …
Merck elects Isabel De Paoli as CSO
September 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
Woodley Equipment Company to Attend ICSE Exhibition, Barcelona
September 26, 2016Clinical Trials Supplier, medical and laboratory equipment provider
Woodley Equipment is attending ICSE Exhibition taking place on 4th to 6th October 2016 at Fira de Barcelona Gran Via, Barcelona, Spain.
FDA gives the green light to the first Humira biosimilar
September 26, 2016Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira
Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …
NICE approval for restricted-use hypophosphatasia therapy
September 23, 2016Medical Communications, Sales and Marketing Alexion Pharmaceuticals, Strensiq, hypophosphatasia
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …
Top ten stories in the pharmaceutical industry this week
September 23, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and …
Alzheimer’s drug failure sends Lundbeck’s shares crashing
September 23, 2016Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings
Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …
Novo Nordisk to provide discounted insulin to poorest nations
September 23, 2016Medical Communications, Sales and Marketing Novo Nordisk, diabetes, insulin
Danish pharma firm Novo Nordisk has announced its intention to provide insulin at discounted prices to the world’s poorest nations …
Novartis’ Zykadia smashes Phase III target for lung cancer
September 23, 2016Medical Communications, Research and Development Novartis, lung cancer, zykadia
Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …
DNA damage response biotech launches with £25m funding
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dna damage response, funding
Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science …
193 countries sign UN declaration to fight drug-resistant infection
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jeremy Hunt, UN, drug-resistant infection
A historic UN declaration to fight drug-resistant infection across the globe has been signed by 193 countries at the United …
Gilead terminates Phase II/III study for ulcerative colitis antibody
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, ulcerative colitis
Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …
AZ withdraws European filing for ovarian cancer therapy
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer
AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
